5

INFORMATION DISCLOSURE CITATION

(Form PTO 1449 Modified) (Use several sheets if necessary)

ATTY. DOCKET NO.
IRVN-007CON2

SERIAL NO.

Unassigned

APPLICANT

Gatanaga, et al.

FILING DATE
Herewith

GROUP

Unassigne

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing l		
K	AA	4,761,371	08/02/1988	Bell et al.					
N	AB	6,083,913	07/04/2000	Dower et al.					
		· .	FOREIG	N PATENT DOCUMENTS				· -	
· · · · · · · · · · · · · · · · · · ·		Document Number	Date	Country	Class	Subclass	Translat	ion	
							Yes	N	
	IAC.	(2000) "ENDDE		Author, Title, Date, Pertinent					
		(2000) "ENBREL(R) (etanercept) U.S. and European Long-Term Clinical Trial Data Presented at the Annua Meeting of the European League Against Rheumatism." Company News On-Call http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=105&STORY=/www/story/06-23-2000/0001250565 (Jun 2000).							
	AD	http://www.immunex.com/investor/pressreleases/pr000719.html (19 Jul. 2000).							
		Lesslauer, et al., "Recombinant soluble tumor necrosis factor recepotr proteins protect mice form lipopolysaccharide-induced lethality," Eur. J. of Immunol. (1991) Vol. 21:2883-2886.							
	AE	<u>lipopolysaccharide</u>	-induced lethality," E	Eur. J. of Immunol. (1991) Vol. 21:2883	-2886.			
	AE AF	lipopolysaccharide Mohler, et al., "Solendotoxemia and f 1993) Vol. 151(3):	-induced lethality," Enable tumor necrosis sunction simultaneous 1548-1561.	Eur. J. of Immunol. (1991 factor (TNF) receptors are sly as both TNF carriers are 12 in combination with the state of the) Vol. 21:2883 re effective ther and TNF Antag	-2886. rapeutic agent onists," <i>J. of</i>	ts in lethal Immunol. (A	_	

F:\forms\word 2k forms\form PTO-1449.doc

EXAMINER

DATE CONSIDERED

9-16-0

EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.